Legend Biotech Corporation (LEGN) Bundle
Ever wondered about the driving force behind cutting-edge cell therapies in the fight against cancer? Legend Biotech Corporation (LEGN), with a market cap of $5.88 billion as of April 2025, stands as a global leader in this innovative field. But how did this biopharmaceutical company, known for its pioneering work in developing and commercializing novel cell therapies, particularly CARVYKTI, emerge and what's the story behind its mission and financial strategies? Delve into the following sections to uncover the history, ownership structure, operational mechanisms, and revenue streams that define Legend Biotech.
Legend Biotech Corporation (LEGN) History
Legend Biotech Corporation Founding Timeline
Year established
Legend Biotech Corporation was established in 2014.
Original location
The company was founded in Nanjing, China.
Founding team members
The key founder is Dr. Fangliang Zhang. He remains a central figure in the company's leadership.
Initial capital/funding
Information regarding the specific initial capital or funding amount at the company's inception isn't readily available in the provided search results. However, it's understood that the company secured substantial investments over time to facilitate its research, development, and clinical programs.
Legend Biotech Corporation Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2014 | Company Founded | Established a base for innovative cell therapies. |
| 2015 | Initial Focus on CAR-T Therapy | Pivoted towards developing CAR-T therapies, setting the stage for future breakthroughs. |
| 2017 | Collaboration with Janssen | Entered into a global collaboration and license agreement with Janssen Biotech to develop, manufacture, and commercialize CAR-T therapy for multiple myeloma. This deal included an upfront payment of $350 million to Legend Biotech. |
| 2020 | Nasdaq IPO | Launched its IPO on the Nasdaq Global Market, raising approximately $423.7 million. |
| 2022 | U.S. FDA Approval of CARVYKTI® | Received FDA approval for CARVYKTI® (ciltacabtagene autoleucel), a CAR-T cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma. |
Legend Biotech Corporation Transformative Moments
- Strategic Collaboration with Janssen: The collaboration with Janssen Biotech in 2017 was a transformative moment, providing significant funding and expertise to advance the development of CAR-T therapy. The initial upfront payment was $350 million.
- FDA Approval of CARVYKTI®: The FDA approval in 2022 for CARVYKTI® marked a pivotal moment, transitioning the company from a research-focused entity to a commercial enterprise with an approved product in the market.
- Successful IPO on NASDAQ: The 2020 IPO provided Legend Biotech with substantial capital, enabling further investment in research and development activities. The IPO raised approximately $423.7 million.
Explore more about the company's purpose and principles: Mission Statement, Vision, & Core Values of Legend Biotech Corporation (LEGN).
Legend Biotech Corporation (LEGN) Ownership Structure
Legend Biotech operates with a mixed ownership structure, featuring a combination of public shareholders and significant institutional investors which shapes its corporate governance and strategic direction.
Legend Biotech's Current Status
Legend Biotech Corporation is a publicly traded company, listed on the NASDAQ under the ticker symbol LEGN. This means that a portion of the company is owned by public investors who can buy and sell shares on the open market. However, it's important to note that while it is public, a significant portion of the company is held by institutional investors and strategic partners.
Legend Biotech's Ownership Breakdown
While precise, real-time ownership percentages fluctuate with market activity, the following table represents a general overview of the ownership structure based on the most recently available data from 2024:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 60-70% | These are typically mutual funds, hedge funds, pension funds, and other large financial institutions that hold significant blocks of shares. Key institutional holders may include entities like BlackRock, Vanguard, and State Street. |
| Public Shareholders | 20-30% | This includes individual investors and smaller investment funds that hold shares traded on the open market. |
| Strategic Partners/Insiders | 10-20% | This may include corporate partners, executive officers, and board members who hold shares either directly or through stock options. For instance, in 2017, GenScript Biotech injected $350 million into the company and currently maintains a substantial equity stake in Legend Biotech. |
Legend Biotech's Leadership
Legend Biotech's leadership team is composed of experienced executives from the biotechnology and pharmaceutical industries. As of April 2025, key figures steering the company include:
- Ying Huang, PhD: Chief Executive Officer.
- Lori MacNeill: Chief Financial Officer.
- Dr. Frank Zhang: Chief Scientific Officer.
These individuals, along with other members of the executive team, are responsible for setting the strategic direction of the company, overseeing operations, and driving innovation in the development of cell therapies.
To gain more insights into Legend Biotech and its investors, check out this resource: Exploring Legend Biotech Corporation (LEGN) Investor Profile: Who’s Buying and Why?
Legend Biotech Corporation (LEGN) Mission and Values
Legend Biotech is dedicated to developing and manufacturing innovative cell therapies to combat cancer. The company values innovation, collaboration, and patient-centricity in its pursuit of transformative treatments.
Legend Biotech's Core Purpose
Official mission statement
Legend Biotech's mission statement is:
- To develop, manufacture, and supply novel cell therapies for unmet medical needs.
- To focus on innovation, quality, and efficiency.
- To transform the treatment landscape for hematological malignancies and solid tumors.
Vision statement
Legend Biotech's vision includes:
- Becoming a global leader in cell therapy.
- Driving cutting-edge research and development.
- Delivering accessible and affordable treatments to patients worldwide.
Company slogan/tagline
Legend Biotech's tagline is not explicitly publicized, but their focus is reflected in their actions:
- Innovating cell therapies for a healthier future.
- Dedicated to transforming cancer treatment.
For more detailed insights, you can explore: Mission Statement, Vision, & Core Values of Legend Biotech Corporation (LEGN).
Legend Biotech Corporation (LEGN) How It Works
Legend Biotech is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing novel cell therapies for oncology and other indications. The company's primary focus is on developing therapies for hematological malignancies, solid tumors, and infectious diseases.
Legend Biotech's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| CARVYKTI® (ciltacabtagene autoleucel) | Adults with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. | CARVYKTI® is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy. It involves collecting a patient's T cells, modifying them to target BCMA on multiple myeloma cells, and then infusing the modified cells back into the patient. |
| Pipeline Programs | Hematological malignancies, solid tumors, and infectious diseases. | Legend Biotech is developing a pipeline of CAR-T cell therapies targeting various cancer antigens and other indications. These programs are in various stages of preclinical and clinical development. |
Legend Biotech's Operational Framework
Legend Biotech operates through an integrated platform that encompasses discovery, clinical development, manufacturing, and commercialization. Key aspects of its operational framework include:
- Research and Development: Legend Biotech invests heavily in R&D to discover and develop innovative cell therapies. This includes preclinical research, clinical trials, and regulatory submissions.
- Manufacturing: The company has established manufacturing capabilities to produce its cell therapies, including CARVYKTI®. This involves cell processing, genetic modification, and quality control.
- Clinical Trials: Legend Biotech conducts clinical trials to evaluate the safety and efficacy of its therapies. These trials are conducted in multiple countries and involve collaborations with leading cancer centers.
- Commercialization: Following regulatory approval, Legend Biotech commercializes its therapies through its own sales force and distribution network. This includes marketing, sales, and patient support services.
- Partnerships: The company collaborates with other biotechnology and pharmaceutical companies to develop and commercialize its therapies. For example, CARVYKTI® is co-developed and co-commercialized with Janssen Biotech, Inc.
Legend Biotech's Strategic Advantages
Legend Biotech's strategic advantages include:
- Innovative Technology: Legend Biotech's CAR-T cell therapy platform is based on innovative technology that has shown promising clinical results in multiple myeloma and other cancers.
- Clinical Data: The company has generated compelling clinical data supporting the safety and efficacy of its therapies. This data has been published in leading medical journals and presented at scientific conferences.
- Manufacturing Capabilities: Legend Biotech has invested in state-of-the-art manufacturing facilities to produce its cell therapies. This enables the company to control the quality and supply of its products.
- Strategic Partnerships: The company's partnerships with other biotechnology and pharmaceutical companies provide access to additional resources and expertise.
- Experienced Management Team: Legend Biotech has an experienced management team with a proven track record of success in the biotechnology industry.
To gain more insights into the values that guide Legend Biotech, explore Mission Statement, Vision, & Core Values of Legend Biotech Corporation (LEGN).
Legend Biotech Corporation (LEGN) How It Makes Money
Legend Biotech Corporation primarily generates revenue through the development, manufacturing, and commercialization of innovative cell therapies, particularly focusing on the treatment of hematologic malignancies. Its primary product is CARVYKTI, which drives the majority of its income.
Legend Biotech's Revenue Breakdown
Legend Biotech's revenue is heavily concentrated in sales of CARVYKTI, but also includes revenue from collaboration agreements.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| CARVYKTI Sales | >90% | Increasing |
| Collaboration Revenue | <10% | Varies |
Legend Biotech's Business Economics
Legend Biotech operates in the competitive field of cell therapy, and its business economics are influenced by several key factors:
- Pricing Strategy: CARVYKTI is priced as a premium product, reflecting its innovative nature and the clinical benefits it offers to patients with relapsed or refractory multiple myeloma. The pricing needs to balance market access, reimbursement considerations, and the value proposition for patients and healthcare providers.
- Manufacturing Costs: As a cell therapy, CARVYKTI involves complex and personalized manufacturing processes. Reducing manufacturing costs while maintaining product quality and consistency is crucial for improving profitability.
- Reimbursement and Market Access: The company's ability to secure favorable reimbursement terms from healthcare payers is vital for driving sales. This involves demonstrating the cost-effectiveness of CARVYKTI compared to other treatment options.
- Partnerships and Collaborations: Strategic alliances, such as the collaboration with Janssen Biotech, are essential for sharing development costs, expanding market reach, and accelerating the commercialization of CARVYKTI.
Legend Biotech's Financial Performance
Legend Biotech's financial performance can be assessed through the following key metrics:
- Revenue Growth: The growth in CARVYKTI sales is a critical indicator of the company's success. Investors monitor sales figures closely to evaluate the market adoption and penetration of the therapy. For the fiscal year 2024, Legend Biotech reported a significant increase in revenue, driven primarily by the expanding global availability and uptake of CARVYKTI.
- R&D Expenses: Legend Biotech invests heavily in research and development to expand its pipeline of cell therapies. These expenses reflect the company's commitment to innovation and its efforts to develop next-generation treatments.
- Operating Expenses: Managing operating expenses, including selling, general, and administrative costs, is essential for achieving profitability. Efficiency in these areas contributes to the company's overall financial health.
- Net Loss/Profit: Due to substantial R&D and commercialization investments, Legend Biotech has historically reported net losses. However, as CARVYKTI sales continue to grow, the company aims to achieve profitability in the coming years.
- Cash Position: Maintaining a strong cash position is crucial for funding ongoing operations, R&D programs, and potential acquisitions.
To gain more insight into Legend Biotech's mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Legend Biotech Corporation (LEGN).
Legend Biotech Corporation (LEGN) Market Position & Future Outlook
Legend Biotech is making strides in the competitive biopharmaceutical market, particularly with its CAR-T cell therapy for multiple myeloma. The company's future hinges on expanding its market reach, navigating regulatory landscapes, and continuing to innovate in cell therapy.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Legend Biotech | ~4% (Global CAR-T cell therapy market) | Strong clinical data for ciltacabtagene, strategic partnerships for global commercialization. |
| Johnson & Johnson | ~30-35% (Global CAR-T cell therapy market) | Established pharmaceutical presence, diverse oncology portfolio, co-commercialization of ciltacabtagene. |
| Bristol Myers Squibb | ~25-30% (Global CAR-T cell therapy market) | Pioneering CAR-T cell therapies, extensive research and development capabilities. |
Note: Market share percentages are approximate and based on the global CAR-T cell therapy market for hematological malignancies as of late 2024 and early 2025. These figures can fluctuate due to new product launches, clinical data updates, and market dynamics.
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expanding indications for ciltacabtagene to earlier lines of multiple myeloma treatment. | Competition from existing and emerging therapies in the multiple myeloma space. |
| Geographic expansion into new markets, particularly in Europe and Asia. | Regulatory hurdles and varying reimbursement landscapes across different countries. |
| Advancing pipeline of novel cell therapies and bispecific antibodies for other hematological malignancies and solid tumors. | Clinical trial failures and delays in product development. |
| Leveraging strategic partnerships to enhance manufacturing capacity and supply chain resilience. | Manufacturing complexities and potential supply chain disruptions. |
| Continued innovation in cell therapy technologies to improve efficacy and reduce toxicity. | High cost of goods and challenges in achieving widespread patient access. |
Industry Position
- Legend Biotech is positioned as a key player in the CAR-T cell therapy space, particularly for multiple myeloma.
- The company's collaboration with a major pharmaceutical company enhances its commercial reach and market penetration.
- Legend Biotech is actively investing in research and development to expand its pipeline and address unmet needs in oncology.
- The company's success depends on its ability to navigate the competitive landscape, secure regulatory approvals, and ensure patient access to its therapies.
To gain more insights into investor behavior and market dynamics, check out: Exploring Legend Biotech Corporation (LEGN) Investor Profile: Who’s Buying and Why?
Legend Biotech Corporation (LEGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.